Maze Therapeutics CEO Jason V. Coloma reports disposal of $1.04 million in common shares

MAZE•2026-11-04

Maze Therapeutics CEO and director Jason V. Coloma sold 34,501 common shares on Nov. 2, 2026, at weighted-average prices ranging from $30.095 to $31.0528 per share.

Maze Therapeutics CEO Jason V. Coloma reports disposal of $1.04 million in common shares

1. Share sale

Related News

Centrus Energy Q3 revenue $55.5 million vs. $57.4 million estimate

Encore Capital Q3 EPS jumps 76% to $5.57

C.H. Robinson increases revolving credit facility to $1.25 billion

Sources

Maze Therapeutics CEO Jason V. Coloma reports disposal of $1.04 million in common shares

Myriad Genetics Q3 net loss widens 60% to $43.9 million; revenue falls to $202.7 million

Clipper Realty Q3 loss widens on NYC lease termination